The similarities and differences with previous models deserve attention: (1) BCLC and CNLC remain the primary staging system for determining treatment methods, while FAAP serves as a complementary, biomarker-based prognostic tool that stratifies risk among patients managed with a similar treatment; (2) Unlike immunotherapy-specific models, Prognostic Nutritional Index (PNI) or PD-L1 expression, FAAP excludes direct immune parameters but may indirectly reflect tumor microenvironment. Here, CD274 is linked to neoplasm.